BNP Paribas Financial Markets Has $333,000 Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

BNP Paribas Financial Markets reduced its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 86.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,690 shares of the life sciences company's stock after selling 97,085 shares during the quarter. BNP Paribas Financial Markets' holdings in Integra LifeSciences were worth $333,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank bought a new stake in Integra LifeSciences in the 4th quarter valued at $8,967,000. Principal Financial Group Inc. boosted its stake in Integra LifeSciences by 5.5% in the 4th quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock valued at $9,603,000 after purchasing an additional 22,000 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in Integra LifeSciences by 7.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after purchasing an additional 913 shares during the period. Nisa Investment Advisors LLC boosted its stake in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Finally, Northern Trust Corp boosted its stake in Integra LifeSciences by 9.9% in the 4th quarter. Northern Trust Corp now owns 892,425 shares of the life sciences company's stock valued at $20,240,000 after purchasing an additional 80,090 shares during the period. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock traded up $0.06 during trading on Friday, reaching $12.74. 1,190,032 shares of the company's stock were exchanged, compared to its average volume of 1,041,229. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences Holdings Co. has a 1-year low of $11.60 and a 1-year high of $32.66. The company has a market cap of $990.05 million, a P/E ratio of -141.54, a PEG ratio of 0.73 and a beta of 1.27. The firm's 50-day moving average price is $16.04 and its 200 day moving average price is $20.92.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same period last year, the firm posted $0.55 EPS. Integra LifeSciences's quarterly revenue was up 3.7% on a year-over-year basis. As a group, research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on IART. JPMorgan Chase & Co. reduced their price target on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. JMP Securities cut their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Truist Financial cut their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, Wells Fargo & Company cut their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Integra LifeSciences currently has an average rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.